Sector: Health Care
Director information for VIATRIS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| David Simmons | Chief Executive Officer | 61 | ["CEO and Public Company Management", "Global Business", "Healthcare Industry", "Strategy and M&A Experience", "Human Capital Management"] | ["Compensation", "Science and Technology", "Compensation Committee", "Science and Technology Committee"] | 2026 |
| Elisha Finney | Independent Director | 64 | ["Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Healthcare Industry", "Human Capital Management", "Information Security", "Risk Oversight/Compliance"] | ["Audit", "Finance"] | 2026 |
| Frank D’Amelio | Independent Director; Chair of the Compensation Committee | 68 | ["Executive Vice President and Chief Financial Officer at Pfizer (2020 - 2022)", "management roles of increasing responsibility at Pfizer (2007 \u2013 2020)", "Senior Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent (2006 - 2007)", "management roles at Lucent Technologies Inc. (2001 - 2006)", "CEO and Public Company Management", "Finance, Accounting, and Capital Markets", "Global Business, and Strategy and M&A Experience", "Human Capital Management", "Healthcare Industry Experience"] | ["Compensation (Chair)", "Finance", "Compensation Committee"] | 2026 |
| James M. Kilts | Independent Director | 78 | ["CEO and Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Global Business", "Strategy and M&A Experience", "Healthcare Industry Experience", "Human Capital Management Experience", "extensive contributions to the Board", "knowledge and familiarity with the acquired Upjohn business", "importance of maintaining continuity of certain legacy Directors"] | ["Compensation", "Finance"] | 2026 |
| JoEllen Lyons Dillon | Independent Director; Chair | 62 | ["Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Global Business", "Human Capital Management", "Information Security", "Legal and Regulatory Oversight", "Risk Oversight/Compliance", "Strategy and M&A", "Experience gained during her almost 25-year legal career in corporate M&A and securities", "Thought leader in corporate governance, legal and regulatory oversight, capital markets, and M&A", "Certification in Board Governance: Navigating Emerging Technologies and More in a Complex World at Cornell University in November 2023"] | ["Audit", "Compensation", "Executive", "Governance and Sustainability (Chair)", "Governance and Sustainability Committee"] | 2026 |
| Leo Groothuis | General Counsel | 53 | ["Corporate Governance", "Global Business", "Legal and Regulatory Oversight", "Risk Oversight/Compliance", "Strategy and M&A"] | ["Compliance and Risk Oversight", "Executive", "Governance and Sustainability", "Governance and Sustainability Committee"] | 2026 |
| Mark Parrish | Vice Chair of the Board | 70 | ["CEO and Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Healthcare Industry", "Risk Oversight/Compliance", "Strategy and M&A", "Global Business", "Human Capital Management", "Information Security"] | ["Compliance and Risk Oversight", "Executive", "Governance and Sustainability", "Science and Technology", "Governance and Sustainability Committee"] | 2026 |
| Melina Higgins | Chair of the Board and Independent Director | 58 | ["Corporate Governance", "Finance", "Accounting", "Capital Markets", "Global Business", "Risk Oversight/Compliance", "Strategy and M&A Experience"] | ["Executive", "Finance", "Chair"] | 2026 |
| Michael Severino, M.D. | Chief Executive Officer; Chair of the Science and Technology Committee | 60 | ["CEO and Public Company Management", "Finance", "Accounting", "Capital Markets", "Global Business", "Strategy and M&A Experience", "Human Capital Management", "Healthcare Industry Experience"] | ["Audit", "Science and Technology", "Chair", "Audit Committee", "Science and Technology Committee"] | 2026 |
| Richard Mark | Chair | [] | [] | 2026 | |
| Richard Mark, C.P.A. | Independent Director | 72 | ["Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Global Business", "Risk Oversight/Compliance", "Strategy and M&A Experience"] | ["Audit", "Compliance and Risk Oversight", "Executive", "Finance"] | 2026 |
| Rogério Vivaldi Coelho, M.D. | Founder and Chief Executive Officer | 62 | ["CEO and Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Healthcare Industry", "Risk Oversight/Compliance", "Strategy and M&A Experience"] | ["Compliance and Risk Oversight", "Science and Technology"] | 2026 |
| Scott A. Smith | Chief Executive Officer and Director; Chief Executive Officer (principal executive officer) | 63 | ["Public Company Management", "Corporate Governance", "Global Business", "Healthcare Industry", "Risk Oversight/Compliance", "Strategy and M&A Experience", "Experience acquired during his more than 35 years in the healthcare industry"] | ["Science and Technology"] | 2026 |
| W. Don Cornwell | Vice Chair | 78 | ["CEO and Public Company Management", "Corporate Governance", "Finance", "Accounting", "Capital Markets", "Global Business", "Strategy and M&A", "Human Capital Management", "Information Security", "Healthcare Industry", "Legal and Regulatory Oversight", "extensive contributions to the Board", "knowledge and familiarity with the acquired Upjohn business", "importance of maintaining continuity of certain legacy Directors"] | ["Audit", "Compliance and Risk Oversight", "Governance and Sustainability", "Compensation", "Executive", "Finance", "Science and Technology", "Governance and Sustainability Committee"] | 2026 |
